Victory Capital Management Inc. Takes $27,000 Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Victory Capital Management Inc. bought a new stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) in the second quarter, Holdings Channel.com reports. The firm bought 10,299 shares of the company’s stock, valued at approximately $27,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Janney Montgomery Scott LLC purchased a new stake in Aquestive Therapeutics in the first quarter valued at approximately $1,456,000. Vanguard Group Inc. raised its position in shares of Aquestive Therapeutics by 71.7% during the 1st quarter. Vanguard Group Inc. now owns 3,242,571 shares of the company’s stock worth $13,813,000 after acquiring an additional 1,353,518 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Aquestive Therapeutics during the 2nd quarter worth approximately $594,000. Jump Financial LLC acquired a new position in Aquestive Therapeutics in the fourth quarter valued at $60,000. Finally, Lazard Asset Management LLC grew its position in shares of Aquestive Therapeutics by 115.5% during the first quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock worth $124,000 after acquiring an additional 15,601 shares during the last quarter. Institutional investors and hedge funds own 32.45% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on AQST. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price target on shares of Aquestive Therapeutics in a report on Monday, August 12th. HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Aquestive Therapeutics in a research report on Wednesday, August 14th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $7.83.

Aquestive Therapeutics Stock Performance

Shares of AQST stock opened at $5.04 on Wednesday. The company’s 50-day simple moving average is $4.11 and its 200-day simple moving average is $3.69. Aquestive Therapeutics, Inc. has a one year low of $1.25 and a one year high of $6.23. The stock has a market capitalization of $458.84 million, a price-to-earnings ratio of -12.00 and a beta of 2.84.

Aquestive Therapeutics (NASDAQ:AQST) last posted its earnings results on Tuesday, August 6th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.08. The firm had revenue of $20.10 million for the quarter, compared to analyst estimates of $12.62 million. During the same period in the previous year, the firm earned ($0.10) earnings per share. As a group, research analysts forecast that Aquestive Therapeutics, Inc. will post -0.47 EPS for the current year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.